These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 6997738)

  • 41. The newly licensed hepatitis B vaccine. Characteristics and indications for use.
    Krugman S
    JAMA; 1982 Apr; 247(14):2012-5. PubMed ID: 7038174
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Response to hepatitis B virus vaccine in subjects with low levels of antibody to hepatitis B surface antigen.
    Perrillo RP; Bodicky C; Campbell C; Sanders GE
    N Engl J Med; 1984 May; 310(22):1463. PubMed ID: 6232460
    [No Abstract]   [Full Text] [Related]  

  • 43. Hepatitis B immune globulin as a prophylactic measure for spouses exposed to acute type B hepatitis.
    Redeker AG; Mosley JW; Gocke DJ; McKee AP; Pollack W
    N Engl J Med; 1975 Nov; 293(21):1055-9. PubMed ID: 1101065
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of heat-inactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial.
    Desmyter J; Colaert J; De Groote G; Reynders M; Reerink-Brongers EE; Lelie PN; Dees PJ; Reesink HW
    Lancet; 1983 Dec; 2(8363):1323-8. PubMed ID: 6139668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff.
    Crosnier J; Jungers P; Couroucé AM; Laplanche A; Benhamou E; Degos F; Lacour B; Prunet P; Cerisier Y; Guesry P
    Lancet; 1981 Feb; 1(8218):455-9. PubMed ID: 6110088
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Large-scale efficacy trials of hepatitis B vaccines in the USA: baseline data and protocols.
    Szmuness W
    J Med Virol; 1979; 4(4):327-40. PubMed ID: 541683
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity of hepatitis B vaccine in Chinese school children: a comparison of two plasma-derived vaccines.
    Lee SD; Lo KJ; Tsai YT; Chan CY; Wu TC; Hwang SJ; Chang CP; Huang YS
    Zhonghua Yi Xue Za Zhi (Taipei); 1988 Aug; 42(2):87-92. PubMed ID: 3066454
    [No Abstract]   [Full Text] [Related]  

  • 48. Hepatitis virus vaccines: present status.
    Krugman S
    Yale J Biol Med; 1982; 55(3-4):375-81. PubMed ID: 6295013
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Impaired responsiveness of homosexual men with HIV antibodies to plasma derived hepatitis B vaccine.
    Carne CA; Weller IV; Waite J; Briggs M; Pearce F; Adler MW; Tedder RS
    Br Med J (Clin Res Ed); 1987 Apr; 294(6576):866-8. PubMed ID: 3105779
    [TBL] [Abstract][Full Text] [Related]  

  • 50. No increased incidence of AIDS in recipients of hepatitis B vaccine.
    Golden JA
    N Engl J Med; 1983 May; 308(19):1163-4. PubMed ID: 6835342
    [No Abstract]   [Full Text] [Related]  

  • 51. Newly licensed hepatitis B vaccine. Known safety and unknown risks.
    Gerety RJ; Tabor E
    JAMA; 1983 Feb; 249(6):745-6. PubMed ID: 6337271
    [No Abstract]   [Full Text] [Related]  

  • 52. Vaccination against hepatitis B in homosexual men. A review.
    Goilav C; Piot P
    Am J Med; 1989 Sep; 87(3A):21S-25S. PubMed ID: 2528293
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Vaccine against human hepatitis B virus prepared from antigen derived from human hepatoma cells in culture.
    McAleer WJ; Markus HZ; Wampler DE; Buynak EB; Miller WJ; Weibel RE; McLean AA; Hilleman MR
    Proc Soc Exp Biol Med; 1984 Mar; 175(3):314-9. PubMed ID: 6320212
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Vaccine against hepatitis B--18 months prevention in a high risk setting.
    Maupas P; Goudeau A; Coursaget P; Drucker J; Bagros P; Baudin S; Geslin N
    Med Microbiol Immunol; 1978 Nov; 166(1-4):109-18. PubMed ID: 723783
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Hepatitis B virus screening in a high-risk college population.
    Campos-Outcalt D
    J Am Coll Health; 1985 Dec; 34(3):120-2. PubMed ID: 4086715
    [No Abstract]   [Full Text] [Related]  

  • 56. Toward the control of hepatitis B.
    Dienstag JL
    N Engl J Med; 1980 Oct; 303(15):874-6. PubMed ID: 7412805
    [No Abstract]   [Full Text] [Related]  

  • 57. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV.
    Biggar RJ; Goedert JJ; Hoofnagle J
    N Engl J Med; 1987 Mar; 316(10):630-1. PubMed ID: 3807959
    [No Abstract]   [Full Text] [Related]  

  • 58. Comparison of safety and immunogenicity of ADW and AYW hepatitis B vaccines.
    Papaevangelou GJ; Vissoulis CG; Roumeliotou-Karayannis AJ; Kolaitis N; Krugman S
    J Med Virol; 1982; 9(3):231-6. PubMed ID: 7047681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-exposure hepatitis B vaccination of sexual partners of acute viral hepatitis patients.
    Papaevangelou G; Roumeliotou-Karayannis A; Tassopoulos N; Kolaitis N; Contoyannis P; Krugman S
    J Infect; 1983 Jul; 7 Suppl 1():63-7. PubMed ID: 6371152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A hepatitis B vaccine.
    S Afr Med J; 1981 Jan; 59(2):29-30. PubMed ID: 7006104
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.